Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received the drug registration certificate for Sildenafil Citrate Orally Disintegrating Tablets from the National Medical Products Administration, indicating compliance with drug registration requirements [1] Group 1: Company Developments - The company submitted the registration application for Sildenafil Citrate Orally Disintegrating Tablets to the Center for Drug Evaluation (CDE) in April 2024, which was accepted [1] - The drug registration certificate was granted in September 2025, with the evaluation conclusion being approval for registration [1] Group 2: Market Context - Sildenafil Citrate Orally Disintegrating Tablets are indicated for the treatment of erectile dysfunction [1] - In 2024, the sales revenue of Sildenafil-related formulations in public medical institutions in China is estimated to be approximately RMB 5.2 billion [1]

格隆汇9月16日丨山东新华制药股份(00719.HK)发布公告，近日，公司的全资子公司山东淄博新达制药 有限公司(以下简称"新达制药")收到国家药品监督管理局核准签发的熊去氧胆酸胶囊《药品注册证 书》。本品用于治疗胆囊胆固醇结石(必须是X射线能穿透的结石，同时胆囊收缩功能须正常)；胆汁淤 积性肝病(如：原发性胆汁性肝硬化)；胆汁反流性胃炎。 ...

本品用于治疗胆囊胆固醇结石(必须是X射线能穿透的结石，同时胆囊收缩功能须正常);胆汁淤积性肝病 (如：塬发性胆汁性肝硬化);胆汁反流性胃炎。 本品属于《国家基本医疗保险、工伤保险和生育保险药品目录(2024年)》甲类品种。根据相关统计数 据，2024年中国公立医疗机构熊去氧胆酸销售额约为人民币21.55亿元。 公告称，新达制药申报的熊去氧胆酸胶囊于2025年9月获得批准，有利于丰富公司消化系统用药品种， 提升公司综合竞争力。 智通财经APP讯，山东新华制药股份(00719)公布，近日，公司的全资子公司山东淄博新达制药有限公司 (以下简称"新达制药")收到国家药品监督管理局核准签发的熊去氧胆酸胶囊《药品注册证书》。 2024年1月，新达制药向国家药品监督管理局药品审评中心(CDE)递交熊去氧胆酸胶囊上市许可申报资 料并获受理，2025年9月获得《药品注册证书》，审评结论为：批准注册。 ...

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Sildenafil Citrate Orally Disintegrating Tablets, which is expected to enhance the company's market competitiveness and open new market opportunities [1]. Company Summary - The company submitted the registration application for Sildenafil Citrate Orally Disintegrating Tablets to the Center for Drug Evaluation (CDE) in April 2024, and the application was accepted [1]. - The drug received its registration certificate in September 2025, with the evaluation conclusion being approval for registration [1]. - The product is indicated for the treatment of erectile dysfunction, a market segment with significant sales potential [1]. Industry Summary - In 2024, the sales revenue of Sildenafil-related formulations in Chinese public medical institutions is estimated to be approximately RMB 5.2 billion [1]. - The approval of this new formulation is expected to contribute positively to the overall market dynamics for erectile dysfunction treatments in China [1].

Core Viewpoint - The report from Debang Securities indicates that the prices of acetylacetone and acetylacetone calcium have increased significantly from their recent lows, suggesting a potential rebound in the PVC environmental additives market due to supply concentration and ongoing environmental policies [1][4]. Price Trends - As of September 9, the prices for acetylacetone and acetylacetone calcium are 17,000 and 19,000 yuan per ton, respectively, marking an increase of 4,000 and 6,000 yuan per ton from their seven-year lows of 13,000 yuan per ton [1][4]. - Current prices are at historical percentiles of 11.94% and 14.86%, with potential upside of approximately 29,500 and 31,000 yuan per ton compared to their highest prices of 46,500 and 50,000 yuan per ton [1][4]. Industry Dynamics - The acetylacetone industry is experiencing supply disruptions alongside steady demand growth, with a notable decline in prices since 2021 leading to some companies exiting the market [3]. - Major domestic producers include Zhejiang Weirong, Jianbang Co., Xinhua Pharmaceutical, and Guangxi Jinyuan, while BASF is a key overseas supplier [3]. - The global acetylacetone market was valued at approximately 338 million USD in 2018 and is projected to grow to 445 million USD by 2025, driven by expanding application areas [3]. Supply and Demand Outlook - The PVC environmental additives market is expected to improve as supply becomes more concentrated and traditional stabilizers face replacement due to environmental regulations [5]. - The industry is likely to undergo a consolidation phase as high-cost capacities exit the market, leading to a potential price rebound for key products [5]. Company Focus - Companies to watch include Jianbang Co. (603285.SH) with acetylacetone salt capacity of 4,240 tons and ongoing projects, Xinhua Pharmaceutical (000756.SZ) with a capacity of 10,000 tons, and Jiaxian Co. (920489.BJ) with DBM/SBM capacities of 7,000 and 3,000 tons, respectively [5][6].

Key Points - China Petroleum & Chemical Corporation (Sinopec) announced a cash dividend of RMB 0.088 per share, totaling RMB 10.662 billion [4] - Guokai Microelectronics is progressing with a share issuance and cash payment to acquire 94.366% of the equity in Zhongxin Integrated Circuit (Ningbo) Co., Ltd. [5][6] - Phoenix Shipping's Vice General Manager Zhao Qiuling resigned due to work adjustments, while Wang Guozheng was appointed as the new financial director [7] - Guokai Co., Ltd. changed its stock abbreviation to Guokai Electronics, effective September 11, 2025 [8] - Xinhua Pharmaceutical's Vice General Manager Zheng Zhonghui resigned for personal reasons, holding 397,600 shares [9] - Uni-President's controlling shareholder's equity structure change was completed, transferring shares from the Ministry of Finance to Central Huijin Investment [10] - ST New Power may face delisting risk due to a negative audit opinion on its internal controls [11] - Huachuang Yuxin announced that 1.87% of its shares held by Shanghai Shiran Industrial Co., Ltd. will be auctioned [12][13] - Zhengbang Technology's subsidiary was accepted for reorganization by the court due to financial difficulties [14] - China Shipbuilding Defense's General Manager Chen Liping resigned due to work changes [15] - ST Lingnan and its former controlling shareholder are under investigation for information disclosure violations [16] - Hikvision's chairman proposed a mid-term dividend of RMB 4 per 10 shares, amounting to RMB 3.666 billion [17] - Huada Jiutian's shareholder plans to transfer 2.64% of the company's shares [18] - Poly Developments reported a signing amount of RMB 18.015 billion in August, a year-on-year decrease of 18.54% [19] - Muyuan Foods reported a revenue of RMB 11.85 billion from selling 7.001 million pigs in August, a year-on-year decrease of 12.30% [20] - Dongrui Co., Ltd. reported a revenue of RMB 160 million from selling 94,800 pigs in August, a month-on-month decrease of 5.48% [21] - Ankai Bus reported a cumulative production increase of 68.06% year-on-year [22] - Kweichow Moutai's controlling shareholder received a loan commitment of up to RMB 2.7 billion for stock repurchase [23] - Chengda Pharmaceutical's major shareholder plans to reduce its stake by 7.27% [24][25] - Kangchen Pharmaceutical's controlling shareholder plans to reduce its stake by up to 3% [26] - Koweil plans to reduce its stake by up to 2.34% [27] - Funeng Technology's shareholders plan to reduce their stake by up to 2% [28] - United Water's shareholder plans to reduce its stake by 3% [29] - Huayin Power's shareholder plans to reduce its stake by 1% [30] - Tianji Co., Ltd. reported a reduction of 0.61% in its controlling shareholder's stake [31] - Tonghuashun's controlling shareholder plans to reduce its stake by up to 138,310 shares [32] - JA Solar has not yet started its share repurchase plan [33] - Beite Technology plans to raise no more than RMB 300 million through a private placement [34] - Aerospace Hongtu signed a strategic cooperation agreement with Pakistan worth RMB 2.9 billion, which is still in preliminary stages [35][36] - Guangqi Technology signed contracts for mass production of metamaterials worth RMB 1.278 billion [37]

分组1 - Sinopec announced a cash dividend of RMB 0.088 per share (tax included) for the first half of 2025, with a total cash dividend distribution of RMB 10.662 billion [3] - Guokai Microelectronics is progressing with the acquisition of a 94.366% stake in Zhongxin Integrated Circuit (Ningbo) Co., Ltd. through a combination of share issuance and cash payment [4] - Phoenix Shipping's Vice President Zhao Qiuling resigned due to work adjustments, while Wang Guozheng was appointed as the new CFO [5] 分组2 - Guokai Microelectronics is actively advancing its major asset restructuring, with due diligence and evaluation processes underway [4] - The stock name of Guokai Co., Ltd. will change to Guokai Electronics starting September 11, 2025 [6] - Xinhua Pharmaceutical's Vice President Zheng Zhonghui resigned for personal reasons, holding 397,600 shares in the company [7] 分组3 - Unified Holdings completed the change in the shareholding structure of its controlling shareholder, with the actual controller changing from the Ministry of Finance to Central Huijin Investment [8] - ST New Power's stock may face delisting risk warnings due to a negative audit opinion on its internal controls for the 2024 financial report [9] - Huachuang Yuxin announced that 1.87% of its shares held by Shanghai Shiran Industrial Co., Ltd. will be auctioned [10] 分组4 - Zhengbang Technology's subsidiary Chaoyang Zhengbang has been accepted for reorganization by the court, with total assets of RMB 332 million and liabilities of RMB 460 million as of December 31, 2024 [11] - China Shipbuilding Defense's General Manager Chen Liping resigned due to work changes [12] 分组5 - Poly Developments reported a signing amount of RMB 18.015 billion in August 2025, a year-on-year decrease of 18.54% [14] - Muyuan Foods reported sales revenue of RMB 11.85 billion from selling 7.001 million pigs in August 2025, with a year-on-year decrease of 12.30% [15] - Dongrui Co., Ltd. reported a sales revenue of RMB 160 million from selling 94,800 pigs in August 2025, a month-on-month decrease of 5.48% [16] 分组6 - Ankai Bus reported a cumulative production increase of 68.06% year-on-year, with a total production of 5,625 vehicles in 2025 [17] - Kangchen Pharmaceutical's controlling shareholder Liu Jianhua plans to reduce his stake by up to 3% [19] - Kewell plans to reduce its shares by up to 2.34% [20] 分组7 - North Special Technology plans to raise no more than RMB 300 million through a private placement for a production base project in Thailand [29] - Guangqi Technology signed contracts worth RMB 1.278 billion for the mass production of metamaterials [31][32]

Group 1 - The core point of the article is the resignation of Zheng Zhonghui, the Deputy General Manager of XinHua Pharmaceutical, due to personal reasons, effective September 5, 2025 [1] - XinHua Pharmaceutical's revenue composition for the first half of 2025 is as follows: 44.36% from chemical drug formulation manufacturing, 32.11% from chemical raw material manufacturing, and 23.53% from pharmaceutical intermediates and others [1] - As of the report, XinHua Pharmaceutical has a market capitalization of 11.4 billion yuan [1]

Core Viewpoint - The resignation of the Vice President of Shandong Xinhua Pharmaceutical Co., Ltd. is officially announced, and it is stated that this will not impact the company's normal operations [1] Group 1: Resignation Announcement - The company received a written resignation report from Vice President Zheng Zhonghui on September 5, 2025, due to personal reasons [1] - Zheng Zhonghui will not hold any executive position in the company after his resignation [1] - The resignation is effective immediately upon delivery to the board of directors [1] Group 2: Impact on Company Operations - As of the announcement date, Zheng Zhonghui has no outstanding commitments that he has failed to fulfill [1] - His resignation will not affect the company's normal production and operational activities [1] - There were no disagreements between Zheng Zhonghui and the board during his tenure [1] Group 3: Shareholding Information - Zheng Zhonghui holds 397,550 A shares of the company, and he will continue to manage his shares according to relevant laws and regulations after his resignation [1] - The board expresses gratitude for Zheng Zhonghui's contributions during his tenure [1]

证券代码：000756 证券简称：新华制药 公告编号：2025-53 董事会谨此对郑忠辉先生在任职期间为公司所做出的贡献表示衷心感谢。 特此公告。 山东新华制药股份有限公司董事会 山东新华制药股份有限公司 关于副总经理辞职的公告 2025 年 9 月 5 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整, 没有虚假记载、误导性陈述 或重大遗漏。 山东新华制药股份有限公司（"公司"）董事会于 2025 年 9 月 5 日收到公司副总经理郑忠辉先 生提交的书面辞职报告。郑忠辉先生因个人原因申请辞去公司副总经理职务，辞职后不在公司担任 高管职务。 根据《公司法》及《公司章程》等有关规定，郑忠辉先生的辞职报告自送达董事会之日起生效。 截止本公告披露日，郑忠辉先生不存在应当履行而未履行的承诺事项，其辞职不会影响公司正常的 生产经营活动，其在任职期间与公司董事会并无意见分歧，也没有任何相关的事项需提请公司股东 注意。 截止本公告披露日，郑忠辉先生持有公司 A 股 397,550 股，其辞职后将继续按照相关法律、法 规及规范性文件的有关规定管理其所持股份。 ...